Anthracosis Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook

Published August 13, 2026 · Data accessed through Patsnap Life Sciences MCP servers.

This Anthracosis Indication Strategy Report ranks the opportunity using disease burden, biological rationale, unmet need, competitive intensity and transaction signals. It is designed for biopharma portfolio, search-and-evaluation, licensing and translational teams. The analysis focuses exclusively on Anthracosis; adjacent diseases are mentioned only when needed to interpret evidence or trial design.

Executive assessment

Anthracosis receives an overall strategic score of 65/100. The opportunity combines an unmet-need score of 78/100, competition score of 64/100 and market-attractiveness score of 72/100. Scores are directional decision aids, not forecasts: they synthesize the MCP evidence returned on the access date and explicitly penalize crowded development landscapes.

Disease background and strategic definition

A diffuse parenchymal lung disease caused by accumulation of inhaled CARBON or coal dust. The disease can progress from asymptomatic anthracosis to massive lung fibrosis. This lung lesion usually occurs in coal MINERS, but can be seen in urban dwellers and tobacco smokers.

For indication strategy, the disease label is only the starting point. A credible target product profile should specify the treatable population, diagnostic pathway, severity threshold, prior-therapy requirements, measurable clinical outcomes and treatment setting. In Anthracosis, value creation will depend on selecting a phenotype that is biologically coherent and commercially reachable, while avoiding a trial population so narrow that recruitment and launch become impractical.

The disease record is identified by Patsnap disease ID e1976a8e843046f7bc8a626008627889 and MeSH identifier D055008. These identifiers help keep searches reproducible when synonyms or spelling variants change.

Epidemiology and disease-burden evidence

Evidence signal 1: The Epidemiology of Hospital-Treated Alopecia Areata in Denmark, 1995–2016 The Epidemiology of Hospital-Treated Alopecia Areatain Denmark, 1995–2016

5. Villasante Fricke AC, Miteva M. Epidemiology and burden of alopecia areata: a systematic review. Clin Cosmet Investig Dermatol. 2015;8:397–403. 6. Mirzoyev SA, Schrum AG, Davis MDP, Torgerson RR. Lifetime incidence risk of alopecia areata esti- mated at 2.1% by Rochester Epidemiology Project, 1990–2009. J Investig Dermatol. 2014;134(4): 1141–2. 7. Muntyanu A, Gabrielli S, Donovan J, et al. The burden of alopecia areata: a scoping review focusing on quality of life, mental health and work produc- tivity. J Eur Acad Dermatol Venereol. 2023;37(8): 1490–520. 8. Harries MJ, Sun J, Paus R, King LE Jr. Management of alopecia areata. BMJ. 2010;341:c3671. 9. Darwin E, Hirt PA, Fertig R, Doliner B, Delcanto G, Jimenez JJ. Alopecia areata: review of epidemiology, clinical features, pathogenesis, and new treatment options. Int J Trichol. 2018;10(2):51–60. 10. Lee JH, Kim HJ, Han KD, et al. Incidence and prevalence of alopecia areata according to subtype: a nationwide, population-based study in South Korea (2006–2015). Br J Dermatol. 2019;181(5): 1092–3. 11. Harries M, Macbeth AE, Holmes S, et al. The epi- demiology of alopecia areata: a population-based cohort study in UK primary care. Br J Dermatol. 2022;186(2):257–65. 12. Benigno M, Anastassopoulos KP, Mostaghimi A, et al. A large cross-sectional survey study of the prevalence of alopecia areata in the United States. Clin Cosmet Investig Dermatol. 2020;13:259–66. 13. Mostaghimi A, Gao W, Ray M, et al. Trends in prevalence and incidence of alopecia areata, alopecia totalis, and alopecia universalis among adults and children in a US

Review the underlying epidemiology source

Evidence signal 2: Prevalence and Incidence of Psoriatic Arthritis among Patients with Psoriasis and Risk Factors for Psoriatic Arthritis in Republic of Korea: A Nationwide Database Cohort Study

Population-based epidemiological studies on disease burden and risk factors for psoriatic arthritis (PsA) in patients with psoriasis (PsO) are limited, especially in Asian populations. Therefore, the aim was to deter- mine the prevalence and incidence of PsA among PsO patients in Korea, and examine associated clinical factors. A cohort study was performed to determine the annual prevalence and incidence of PsA among PsO patients between 2008 and 2020 using nation- wide claims data in Korea. Risk factors for PsA deve- lopment were also examined using logistic regression among matched PsA cases and controls. An increasing trend in PsA prevalence per 1,000 patients was obser- ved; prevalence was 6.17 (95% confidence interval [CI] 5.73–6.65) in 2008 and 19.03 (95% CI 18.39– 19.70) in 2020. Similarly, the PsA incidence rate per 1,000 patient-years increased from 3.35 (95% CI 3.01–3.72) in 2008 to 5.01 (95% CI 4.68–5.36) in 2020. Patients with plaque PsO, moderate-to severe PsO, receiving oral systemic therapy or phototherapy, with a higher burden of comorbidities, and concomi- tant autoimmune diseases had a higher risk of PsA. The results provide insight into the burden of PsA among PsO patients in Korea and risk factors associa- ted with developing PsA. Key words: epidemiology; incidence; prevalence; psoriasis; psoriatic arthritis; risk factor. Submitted Feb 18, 2024. Accepted after revision Aug 14, 2024 Publihed Sep 19, 2024. DOI: 10.2340/actadv.v104.40110 Acta Derm Venereol 2024; 104: adv40110. Corr: Chul Jong Park, MD, PhD, Department of Dermatology, Bucheon St. Mary’s Hospi

Review the underlying epidemiology source

Evidence signal 3: Annual epidemiological report Reporting on 2010 surveillance data and 2011 epidemic intelligence data Hepatitis C virus infection

Anthrax is an infectious disease, caused by the bacte­ rium Bacillus anthracis. It is an environmental micro­ organism which is capable of forming spores that can remain dormant in soil for many years. There are three forms of the disease: cutaneous, digestive and res­ piratory. The cutaneous form is the most common and occurs when spores of Bacillus anthracis are introduced into the skin through an abrasion or cut. The gastroin­ testinal form occurs after eating meat from an infected animal. The symptoms are similar to food poisoning and can be severe. Pulmonary anthrax occurs by inhalation of the spores. Initial symptoms are similar to those of a common cold, but this can rapidly progress to severe breathing difficulties and fatal shock. Anthrax still occurs naturally in both animals and humans in many parts of the world, including Asia, southern Europe, sub-Saharan Africa and parts of Australia. In Europe, sporadic cases are reported every year, mainly due to occupational exposure to infected animals or their products. Epidemiological situation in 2010 In 2010, 25 EU/EEA countries provided data on anthrax (Denmark, Iceland, Italy and Liechtenstein did not report). Overall, 32 cases of anthrax were reported; 28 from the United Kingdom, three from Bulgaria and one from Germany. In 2009, 14 cases were reported (Table 2.3.1)1. The overall rate of confirmed cases was 0.01 per 100000. With regard to gender distribution of cases with known data, 21 cases were male and eight female (male to female ratio: 2.6:1) (Figure 2.3.1). Most of the cases (27 of 32) belonged to the age gro

Review the underlying epidemiology source

Epidemiology must be translated into an addressable population rather than copied into a revenue model. The recommended funnel is total prevalent or incident population → diagnosed population → clinically eligible segment → treated population → realistically accessible population. Analysts should separate point prevalence from lifetime prevalence, distinguish incidence from diagnosis rates, and avoid combining incompatible geographies or age bands.

For Anthracosis, the highest-value next epidemiology work is to quantify diagnostic delay, severity distribution, current treatment penetration and the proportion managed in specialist centers. Those variables often move the commercial case more than a single headline prevalence statistic.

Unmet need and patient-value thesis

Unmet need in Anthracosis should be framed as a measurable gap: inadequate disease control, treatment-limiting toxicity, burdensome administration, irreversible progression, delayed diagnosis, weak durability or lack of options for a defined subgroup. A program is strategically attractive when its mechanism can plausibly change one of those outcomes and when the clinical endpoint is accepted by regulators, physicians and payers.

The strongest development thesis would connect mechanism to a pre-specified responder population, demonstrate a clinically interpretable benefit, and reduce a meaningful part of the care burden. A weak thesis would rely only on statistical significance, use an endpoint disconnected from daily function, or assume that rarity automatically supports premium pricing.

Target mechanism: IL-6

IL6 is a potent inducer of the acute phase response. Rapid production of IL6 contributes to host defense during infection and tissue injury, but excessive IL6 synthesis is involved in disease pathology. In the innate immune response, is synthesized by myeloid cells, such as macrophages and dendritic cells, upon recognition of pathogens through toll-like receptors (TLRs) at the site of infection or tissue injury (Probable). In the adaptive immune response, is required for the differentiation of B cells into immunoglobulin-secreting cells. Plays a major role in the differentiation of CD4(+) T cell subsets. Essential factor for the development of T follicular helper (Tfh) cells that are required for the induction of germinal-center formation. Required to drive naive CD4(+) T cells to the Th17 lineage. Also required for proliferation of myeloma cells and the survival of plasmablast cells (By similarity). Acts as an essential factor in bone homeostasis and on vessels directly or indirectly by induction of VEGF, resulting in increased angiogenesis activity and vascular permeability (PubMed:12794819, PubMed:17075861). Induces, through 'trans-signaling' and synergistically with IL1B and TNF, the production of VEGF (PubMed:12794819). Involved in metabolic controls, is discharged into the bloodstream after muscle contraction increasing lipolysis and improving insulin resistance (PubMed:20823453). 'Trans-signaling' in central nervous system also regulates energy and glucose homeostasis (By similarity). Mediates, through GLP-1, crosstalk between insulin-sensitive tissues, intestinal L cells and pancreatic islets to adapt to changes in insulin demand (By similarity). Also acts as a myokine (Probable). Plays a protective role during liver injury, being required for maintenance of tissue regeneration (By similarity). Also has a pivotal role in iron metabolism by regulating HAMP/hepcidin expression upon inflammation or bacterial infection (PubMed:15124018). Through activation of IL6ST-YAP-NOTCH pathway, induces inflammation-induced epithelial regeneration (By similarity). Cytokine with a wide variety of biological functions in immunity, tissue regeneration, and metabolism. Binds to IL6R, then the complex associates to the signaling subunit IL6ST/gp130 to trigger the intracellular IL6-signaling pathway (Probable). The interaction with the membrane-bound IL6R and IL6ST stimulates 'classic signaling', whereas the binding of IL6 and soluble IL6R to IL6ST stimulates 'trans-signaling'. Alternatively, 'cluster signaling' occurs when membrane-bound IL6:IL6R complexes on transmitter cells activate IL6ST receptors on neighboring receiver cells (Probable).

The proposed mechanism anchor for this landscape is IL6. Target selection does not imply that every Anthracosis patient is target-dependent. The translational package should establish expression or pathway activity in the intended tissue, human genetic or biomarker support, pharmacodynamic tractability, a therapeutic window and evidence that target modulation changes disease-relevant biology.

Critical de-risking experiments include orthogonal target engagement assays, dose–response work in disease-relevant models, biomarker qualification, assessment of compensatory pathways and explicit off-target safety testing. Human evidence should be weighted above model-only evidence, and negative clinical results in related mechanisms should be treated as learning assets rather than ignored.

Clinical development and competitive landscape

The MCP search returned 15 matched registered studies overall. The most recent records sampled for this report are:

• ChiCTR2300079153 — Study on circulating miRNA as molecular maker for early diagnosis of coal workers' pneumoconiosis; status: Not yet recruiting; phase: Early Phase 1; sponsor(s): not stated; enrollment: 5.
• ChiCTR2200066697 — Clinical study on feibi granule in treating patients with coal worker's pneumoconiosis in remission stage; status: Not yet recruiting; phase: Early Phase 1; sponsor(s): Beijing Municipal Health Bureau, Beijing Fangshan District First Hospital; enrollment: 47.
• ChiCTR2200063723 — Clinical research on improving the quality of life and exercise tolerance of patients with pneumoconiosis with breathing-guided rehabilitation technology: A prospective clinical study; status: Notyet recruiting; phase: Not Applicable; sponsor(s): not stated; enrollment: 52.

Raw trial count is not the same as commercial competition. Each program should be normalized by phase, modality, mechanism, sponsor strength, recruitment status, geography and the exact patient segment. Observational or investigator-led studies may reveal endpoint conventions and recruitment networks without representing product competition; discontinued assets may still expose safety or efficacy risks.

A differentiated Anthracosis program should define its advantage against the standard of care and the likely future standard at launch, not merely today's comparator. Useful whitespace can come from earlier intervention, a biomarker-selected subgroup, superior durability, safer chronic use, simpler delivery or a combination strategy with a clear contribution from each component.

Transactions and partnering attractiveness

No directly matched 2023–2026 transaction was returned for Anthracosis. This is decision-relevant negative evidence: the indication may be under-transacted, may trade through broader disease labels, or may require target- and asset-level deal searches. It should not be interpreted as proof of zero partnering activity.

Transaction evidence should be interpreted alongside asset quality. Headline values may include contingent milestones, broad platform rights, multiple indications or undisclosed options. A defensible comparable set therefore requires matching disease, target, modality, development phase, territory and deal structure. Where direct comparables are sparse, triangulation across target-level and therapeutic-area transactions is preferable to forcing an unrelated deal into the valuation.

Potential partners will expect a concise evidence room: disease segmentation, target-validation chain, competitive map, clinical development plan, intellectual-property position, chemistry or manufacturability evidence and a transparent risk-adjusted value model. Early outreach is most productive when the program has a clear upcoming catalyst and a credible explanation of why the asset can win specifically in Anthracosis.

Market attractiveness and access considerations

The market opportunity is shaped by more than patient count. Diagnosis infrastructure, concentration of prescribers, treatment duration, administration setting, payer controls, competing generics, monitoring requirements and geographic reimbursement all influence attainable value. For Anthracosis, a launch model should test conservative, base and upside scenarios rather than assume uniform diagnosis and treatment.

Pricing power will depend on magnitude and durability of benefit, evidence quality, alternatives and budget impact. Developers should begin payer research before pivotal design so that endpoints, comparators and follow-up duration support both regulatory approval and reimbursement. Evidence generation should include health-resource use, quality of life and treatment burden when those are central to the value proposition.

Risks, evidence gaps and decision gates

• Disease-definition risk: validate that the proposed population is consistently diagnosed and recruitable.
• Biology risk: demonstrate that IL6 is causal or therapeutically relevant in the intended subgroup.
• Translation risk: link target engagement to a biomarker and a clinically meaningful endpoint.
• Competition risk: refresh the landscape before each investment gate and include mechanisms likely to launch first.
• Commercial risk: test diagnosis, access, pricing and adoption assumptions with physicians and payers.
• Data risk: treat zero-result searches as prompts for synonym and roll-up analysis, not definitive absence.

The recommended decision gates are: confirm epidemiology and segmentation; validate target biology in human evidence; establish a differentiated target product profile; obtain early clinical proof of mechanism; and only then scale investment toward registrational development or partnering. Each gate should have pre-agreed stop criteria.

Strategic recommendation

Anthracosis merits continued evaluation with an evidence-led, milestone-based strategy. The current signal supports prioritizing a narrowly defined population where IL6 biology can be measured and where the clinical benefit would be meaningful relative to available care. The program should advance only if follow-up work confirms population size, mechanistic coherence, endpoint feasibility and a credible route to differentiation.

For business development, the near-term goal is not to maximize the number of outreach targets; it is to assemble a partner-ready thesis that explains the patient segment, mechanism, competitive whitespace, development path and value-inflection milestones. The scores in this report provide a common language for comparing the opportunity while preserving the underlying evidence and uncertainties.

Methodology and source note

This report was assembled on August 13, 2026 using Patsnap MCP tools in a reproducible sequence: disease profile retrieval, epidemiology semantic search, target profile retrieval, clinical-trial search and pharmaceutical-deal search. Results reflect the returned records and query scope on that date. Counts may change as databases update, and the analysis is not medical, regulatory or investment advice.

The ranking weights are 40% unmet need, 25% inverse competitive intensity and 35% market attractiveness. Qualitative judgments are informed by disease-profile depth, epidemiology coverage, registered-trial activity, development-drug counts and direct recent transaction signals. Readers should rerun searches with synonyms, disease roll-ups, target names and asset filters before a transaction or portfolio decision.

Conclusion

Anthracosis offers a tractable strategic question: can a biologically grounded program deliver a material patient benefit in a clearly identifiable population and do so with sufficient differentiation to earn adoption? The evidence assembled here gives teams a starting map, while the identified gaps define the next diligence plan. Use the linked MCP marketplace to refresh the evidence as programs, trials and transactions evolve.